A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
J Pain Res
; 10: 2413-2424, 2017.
Article
in En
| MEDLINE
| ID: mdl-29062240
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
J Pain Res
Year:
2017
Document type:
Article
Affiliation country: